Evidence map›Paper›PMID 26968847›Full record

Trial reportJournal of cutaneous pathology2016

The self-reported use of immunostains and cytogenetic testing in the diagnosis of melanoma by practicing U.S. pathologists of 10 selected states.

Ge Zhao, Kachiu C Lee, Gina Kwon, Paul D Frederick, Tracy L Onega, Michael W Piepkorn, Stevan Knezevich, Raymond L Barnhill, David E Elder, Joann G Elmore

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cutaneous pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Ge ZhaoDivision of Dermatology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Kachiu C LeeDepartment of Dermatology, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Gina KwonDivision of Dermatology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Paul D FrederickDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Tracy L OnegaDepartment of Biomedical Data Science, Norris Cotton Cancer Center, Lebanon, NH, USA.
Michael W PiepkornDivision of Dermatology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Stevan KnezevichPathology Associates, Clovis, CA, USA.
Raymond L BarnhillDepartment of Pathology, Faculty of Medicine, University of Paris Descartes, Paris, France.
David E ElderDepartment of Pathology, University of Pennsylvania, Philadelphia, PA, USA.
Joann G ElmoreDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
University of Washington · USClovis Oncology (United States) · USDartmouth Institute for Health Policy and Clinical Practice · USDélégation Paris 5 · FRHarvard University · USUniversity of Pennsylvania · US

Funding

Accuracy in the Diagnosis of Melanoma & the Impact of Double ReadingR01CA151306 · NCI · UNIVERSITY OF WASHINGTON · PI ELMORE, JOANN G · 2011 to 2015
$4.1M
Improving Accuracy &Outcomes of Breast Cancer ScreeningK05CA104699 · NCI · UNIVERSITY OF WASHINGTON · PI ELMORE, JOANN G · 2004 to 2014
$1.2M
Training for Investigative DermatologyT32AR056969 · NIAMS · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2009 to 2013
$813k
NCI NIH HHS K05 CA104699NCI NIH HHS R01 CA151306NIAMS NIH HHS T32 AR056969
6 · The paper itself

Abstract

backgroundsThe diagnosis of melanoma can be challenging, especially in lesions for which the histopathologic criteria bridge two or more taxonomic categories. Newer genomic analytical methods of fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) have been introduced as ancillary techniques to differentiate benign and malignant melanocytic proliferations.

methodsWe evaluated how pathologists perceive and are incorporating these new cytogenetic testing technologies into their practices. We conducted a study of 207 U.S. pathologists who interpret melanocytic lesions in clinical practice in 10 SEER states. Pathologists were surveyed regarding perceptions and utilization of FISH and/or CGH in their clinical practices.

resultsResults showed that 38% of pathologists use FISH and/or CGH in interpreting melanocytic lesions. Pathologists reporting FISH and/or CGH use were significantly younger (p < 0.05), were fellowship trained or board certified in dermatopathology (p < 0.001) and were affiliated with an academic institute (p < 0.001). Pathologists reporting that their colleagues consider them an expert in the assessment of melanocytic lesions were more likely to employ FISH and/or CGH in their practices than non-experts.

conclusionsEarly users of cytogenetic testing technologies in cutaneous pathology are more likely to be younger, affiliated with an academic institution and fellowship trained or board certified in dermatopathology.

Indexed as

In Situ Hybridization, FluorescenceMelanomaSelf MedicationSelf ReportAdultAgedFemaleHumansImmunosuppressive AgentsMaleMiddle AgedUnited StatesImmunosuppressive AgentsCGHdermatopathologyFISH

Identifiers

PMID26968847
PMCPMC5592970
OpenAlexW2300985269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.